Where to get compounded tirzepatide in 2026

Where to get compounded tirzepatide: the short answer

If you are searching for where to get compounded tirzepatide in 2026, the honest answer is that the market you may remember from 2023 or 2024 mostly does not exist anymore. Large-scale 503B outsourcing facilities, the ones that supplied most telehealth programs at volume, lost their legal ability to compound tirzepatide when the FDA resolved the national shortage. What is left is a narrow, prescription-specific pathway through individual 503A pharmacies, plus a gray market you should avoid entirely.

This guide covers both legitimate routes, what actually has to be true for a 503A pharmacy to compound it for you, and how the economics compare to just paying for brand-name Zepbound now that its price has come down.

Route one: a 503A pharmacy with documented medical need

A 503A compounding pharmacy fills individual prescriptions under your state pharmacy board's oversight. It can still legally compound tirzepatide, but the bar has moved. Before the shortage ended, the justification was simply that tirzepatide was hard to get. Now the prescriber has to document a specific reason the commercial product, Zepbound or Mounjaro, will not work for that patient.

A confirmed allergy to an inactive ingredient in Zepbound, such as one of the buffer components, is a recognized reason. A dose that does not exist in the commercial pen is sometimes a reason. Preferring a lower price, wanting a multi-dose vial instead of a pen, or general availability concerns are not. The FDA's rule against compounding something that is "essentially a copy" of an approved drug is the operative constraint here, and it is why a pharmacy cannot simply hand you the same molecule at the same dose for less money.

Route two: telehealth programs still offering it

Some online programs still work with 503A pharmacies and will evaluate whether you qualify for compounded tirzepatide under the current rules. This looks different from the 2023 model, where compounded tirzepatide was offered by default because brand-name supply could not keep up with demand. Now it is a clinical exception, reviewed case by case, and not every provider still does this review. Others have quietly dropped tirzepatide from what they offer and now route patients straight to brand-name prescriptions instead.

Because this shifts month to month, the only reliable way to know what a specific program currently offers is to check directly. Do not rely on a listing or comparison you read months ago.

How to verify a pharmacy before you pay

Whichever route you go, the pharmacy actually making your medication matters more than the telehealth brand in front of it. Ask for the name of the compounding pharmacy, not just confirmation that "a licensed pharmacy" is involved. Then check it yourself.

A pharmacy with nothing to hide will answer all four questions without hesitation. For the full picture on how 503A and 503B pharmacies differ and what regulation actually requires, see what is a compounding pharmacy.

What to avoid: the gray market

Separate from licensed compounding entirely is the gray market: raw tirzepatide bought from unauthorized chemical suppliers, often overseas, sold as "research use only" with no prescription and no pharmacist involved. This is not a cheaper version of the same thing. It is an unregulated product with no chain of custody.

The FDA has documented gray-market and counterfeit GLP-1 products arriving contaminated, discolored, or containing visible particulate matter. Independent testing of unregulated peptide products has found impurity rates as high as 86%, along with dosing that varies from the label by 50% or more. There is no pharmacist checking the batch and no one accountable if the vial is wrong. If a price looks too low to be a licensed 503A product, it probably is not one.

Do the economics still favor compounded?

This is the part that has genuinely changed since 2023. Compounded tirzepatide through a legitimate 503A pharmacy still runs roughly $250 to $500 a month. But Zepbound through LillyDirect now costs $299 to $449 a month depending on dose, without insurance. Medicare Part D enrollees can get it for $50 a month under the Medicare GLP-1 Bridge, which started July 1, 2026. When compounded was $150 to $200 cheaper than a brand product with no self-pay option, the cost case was obvious. At current prices, it is a lot closer, and the brand product comes with FDA-reviewed manufacturing and a standardized dose.

For a full cost breakdown across both options, see tirzepatide online cost, and for the underlying legal question, see is compounded tirzepatide legal in 2026. For the broader compounding landscape across every GLP-1, see compounded GLP-1s in 2026, and for how the new Medicare pricing works, see Medicare GLP-1 coverage starting July 2026.

The bottom line

Compounded tirzepatide has not disappeared, but it is no longer the default cheap alternative it was. It is now a narrow clinical exception, available through a licensed 503A pharmacy only when the commercial product genuinely does not work for you, and increasingly hard to distinguish from brand-name pricing anyway. If you are searching for where to get it, start with a program willing to do that clinical review honestly, verify the pharmacy yourself, and stay away from anything sold outside a prescription.